Abstract:Purpose: There are currently no ideal indicators for predicting the cardiovascular risk of obstructive sleep apnea (OSA). This study aimed to employ urinary metabolomics to detect early cardiovascular risk in patients with moderate-to-severe OSA. Patients and methods: Male participants who underwent polysomnography from November 2020 to May 2021 were screened. Clinical data, polysomnography data and urine samples were collected. Untargeted metabolomics analyses of urine were performed. Multivariate analyses and receiver operating characteristic (ROC) curve analyses were subsequently performed to identify potential biomarkers. Associations between metabolites and clinical indicators and cardiovascular risk were examined through linear regression analyses with interaction and mediation analyses. Results: Thirty-six male participants were included in the study, comprising 22 males with moderate-to-severe OSA and 14 age-matched controls, with an average age of 39.6 ± 9.2 years. We identified 65 metabolites in the study, involving pathways including pyrimidine, androgen, estrogen, vitamin B6 and sulfate/sulfite metabolism. Among them, epinephrine sulfate was the most significantly altered metabolite. ROC analyses highlighted that epinephrine sulfate had the highest area under the curve (AUC=0.883) for detecting moderate-to-severe OSA. Epinephrine sulfate was statistically correlated with OSA severity, hypoxia-related indicators (apnea-hypopnea index: r=0.685; oxygen desaturation index: r=0.743, p<0.0001), arterial stiffness (arterial augmentation index: r=0.361, p=0.031) and long-term cardiovascular risk (Framingham cardiovascular risk: r=0.375, p=0.024). Linear regression analysis revealed that epinephrine sulfate was significantly associated with an increased in the Framingham risk (β = 0.004, 95% CI = 0.000-0.009, p = 0.049), with the effect partly mediated by systolic blood pressure (27.6%) and not moderated by other factors. Additionally, it also significantly associated with the increased in the arterial augmentation index (β = 0.019, 95% CI = 0.000-0.037, p = 0.046), with the effect fully mediated by blood pressure and not moderated by other indices statistically. Conclusion: There are significant metabolic pathway alterations in moderate-to-severe OSA patients. Urinary epinephrine sulfate markedly predicts early cardiovascular risk in OSA patients.

Serum uric acid is related to left ventricular geometry and function in patients with obstructive sleep apnea

Association of serum uric acid with all-cause and cardiovascular mortality in obstructive sleep apnea

Association of Serum Uric Acid and Cardiovascular Events in Patients with Obstructive Sleep Apnea

Serum Uric Acid Is Independently Associated with Risk of Obstructive Sleep Apnea-Hypopnea Syndrome in Chinese Patients with Type 2 Diabetes

The relationship between obstructive sleep apnea-hypopnea syndrome and blood uric acid levels

Serum uric acid and arterial lactate levels in patients with obstructive sleep apnea syndrome: the effect of CPAP treatment

Circulating markers of oxidative stress and risk of incident cardiovascular events in obstructive sleep apnea

Influnce of Obstructive Sleep Apnea Hypopnea Syndrome to the Levels of Serum Uric Acid and Blood Lipid

Urinary metabolomic biomarkers predict early cardiovascular risk in moderate-to-severe obstructive sleep apnea

Changes of serum myocardial enzymes and uric acid in patients with severe obstructive sleep apnea hypopnea syn-drome complicated with hypertension

Correlation between serum uric acid and pulmonary arterial hypertension based on echo probability in patients with obstructive sleep apnea syndrome

Research on Serum Amyloid A Protein Levels in Patients with Obstructive Sleep Apnea

Clinical Utility of Biochemical Markers of Obstructive Sleep Apnea

Serum advanced glycation end products are associated with insulin resistance in male nondiabetic patients with obstructive sleep apnea

Serum Level of Vascular Endothelial Growth Factor in Patients with Obstructive Sleep Apnea Hypopnea Syndrome.

Relationship between serum levels of endogenous secretory RAGE and blood pressure in male nondiabetic patients with obstructive sleep apnea

Urinary Epinephrine Sulfate Can Predict Cardiovascular Risk in Moderate-to-Severe OSA: A Metabolomics-Based Study

Effects of obstructive sleep apnea on inflammatory markers in patients with acute coronary syndrome

Serum uric acid and its relationship with cardiovascular risk profile in Chinese patients with early-onset coronary artery disease

Higher body mass index is associated with higher hyperurcemia in patients with obesity and obstructive sleep apnea

Urine biomarkers of renal renin-angiotensin system activity: Exploratory analysis in humans with and without obstructive sleep apnea